BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of…

Posted: December 7, 2024 at 2:50 am

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag

Originally posted here:
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of...

Related Posts